

U.S. Patent and Trademark Office
PTOL-413B (04-03)

Examiner Initiated Interview Summary

Paper No. 20040416

Continuation of Substance of Interview including description of the general nature of what was discussed: It was agreed that claims 1, 2, and 4 would be amended to more clearly refer to the IMPDH inhibitor VX-148. It was agreed that claims 1 and 2 would be amended to remove language describing optimal compositions because, while it is clear that the composition has been optimized by one set of standards, it is unclear as to what other forms of optimization might be employed to generate an optimal compound..